Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylphenidate extended release - Aytu BioPharma

Next Previous
X
Search
Drug Profile

Methylphenidate extended release - Aytu BioPharma

Alternative Names: Cotempla XR-ODT; Methylphenidate extended-release orally disintegrating tablet; Methylphenidate XR-ODT; NT-0102

Latest Information Update: 02 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neos Therapeutics
  • Developer Aytu BioPharma
  • Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 31 Jul 2023 Aytu Biopharma and Medomie Pharma entered into an exclusive collaboration, distribution and supply agreement to commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian
  • 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
  • 13 Mar 2020 Neos Therapeutics announces intention to launch methylphenidate extended release for Attention deficit hyperactivity disorder in Puerto Rico in the second quarter of 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top